In a US health care system based largely on fixing problems rather than preventing them, looking for diseases in asymptomatic populations has always been controversial. Concerns around cost-effectiveness and the need to definitively link therapies to improved outcomes have prevented the adoption of screening paradigms for more than a handful of conditions. Diabetes became one of them in January 2005, when CMS added it to its list of reimbursed tests, paving the way for VeraLight Inc. , a new company developing a noninvasive alternative to fasting blood glucose, which is the current standard diabetes screening test.
In fact, a number of factors have come together recently, creating the perfect storm for VeraLight’s diabetes screening technology, says...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?